2026-06-14T02:29:10Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/138842025-04-24T18:32:37Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609
Repisalud
author
Vigon-Hernandez, Lorena
author
Fuertes, Daniel
author
García-Pérez, Javier
author
Torres, Montserrat
author
Rodríguez-Mora, Sara
author
Mateos, Elena
author
Corona, Magdalena
author
Saez-Marín, Adolfo J.
author
Malo de Molina, Rosa
author
Navarro, Cristina
author
Murciano-Antón, María Aranzazu
author
Cervero, Miguel
author
Alcamí, José
author
García-Gutiérrez, Valentín
author
Planelles, Vicente
author
Lopez-Huertas, Maria Rosa
author
Coiras, Mayte
author
Multidisciplinary Group of Study of COVID-19 (MGS-COVID)
funder
National Institutes of Health (Estados Unidos)
funder
Red de Investigación Cooperativa en Investigación en Sida (España)
funder
Instituto de Salud Carlos III
funder
Ministerio de Ciencia e Innovación (España)
funder
World Health Organization (WHO/OMS)
funder
Chiesi Foundation
funder
Ministerio de Economía y Competitividad (España)
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
National Institutes of Health (Estados Unidos)
2022-03-29T11:08:47Z
2022-03-29T11:08:47Z
2021-05
Front Immunol. 2021 May 26;12:665329.
10.3389/fimmu.2021.665329
1664-3224
Frontiers in Immunology
34122423
http://hdl.handle.net/20.500.12105/13884
Infection by novel coronavirus SARS-CoV-2 causes different presentations of COVID-19 and some patients may progress to a critical, fatal form of the disease that requires their admission to ICU and invasive mechanical ventilation. In order to predict in advance which patients could be more susceptible to develop a critical form of COVID-19, it is essential to define the most adequate biomarkers. In this study, we analyzed several parameters related to the cellular immune response in blood samples from 109 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centers in Madrid, Spain, during the first pandemic peak between April and June 2020. Hospitalized patients with the most severe forms of COVID-19 showed a potent inflammatory response that was not translated into an efficient immune response. Despite the high levels of effector cytotoxic cell populations such as NK, NKT and CD8+ T cells, they displayed immune exhaustion markers and poor cytotoxic functionality against target cells infected with pseudotyped SARS-CoV-2 or cells lacking MHC class I molecules. Moreover, patients with critical COVID-19 showed low levels of the highly cytotoxic TCRγδ+ CD8+ T cell subpopulation. Conversely, CD4 count was greatly reduced in association to high levels of Tregs, low plasma IL-2 and impaired Th1 differentiation. The relative importance of these immunological parameters to predict COVID-19 severity was analyzed by Random Forest algorithm and we concluded that the most important features were related to an efficient cytotoxic response. Therefore, efforts to fight against SARS-CoV-2 infection should be focused not only to decrease the disproportionate inflammatory response, but also to elicit an efficient cytotoxic response against the infected cells and to reduce viral replication.
eng
CD8 lymphocytes +
COVID-19
NK and NKT cells
SARS-CoV-2
Cytotoxic response
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity
research article
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
URL
https://repisalud.isciii.es/bitstreams/6037398e-7bc1-4cfc-8b63-5f7cc41dc33c/download
File
MD5
12929628b101661b16b604e8a67b76db
7046016
application/pdf
ImpairedCytotoxicResponseIn_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/ca342d60-9984-4c52-89ba-6c5a3b438f36/download
File
MD5
bd94e1a68788b2de835b267e1c7d8455
34015
application/vnd.openxmlformats-officedocument.wordprocessingml.document
ImpairedCytotoxicResponseInTable_1_2021.docx
URL
https://repisalud.isciii.es/bitstreams/5f174bb6-2456-414d-bacf-5b29bddbe9b8/download
File
MD5
947e9006ae01bc46e30ad97fa87b882c
54798
application/vnd.openxmlformats-officedocument.wordprocessingml.document
ImpairedCytotoxicResponseInTable_2_2021.docx
URL
https://repisalud.isciii.es/bitstreams/5574901b-d1e5-4298-9c36-406ced20ef45/download
File
MD5
49c25c5114e63508daa5ace5f226f544
63572
text/plain
ImpairedCytotoxicResponseIn_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/abefcbcb-bee4-4675-a46b-f6bf7c8c990b/download
File
MD5
6b5347b9c9ce8b4c451c5cca06d1ae04
4799
text/plain
ImpairedCytotoxicResponseInTable_1_2021.docx.txt
URL
https://repisalud.isciii.es/bitstreams/ce22f135-8c49-426a-a58d-c0f400d7f58a/download
File
MD5
b82127b4c7f6f1fac6ab00d0c64fdbe8
13031
text/plain
ImpairedCytotoxicResponseInTable_2_2021.docx.txt